title: Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
abstract: In a double-blind, placebo controlled study, ipriflavone (600 mg/day, T.D.D.) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with the gonadotropin hormone-releasing hormone agonist (Gn-RH-A) leuproreline acetate, 3.75 mg every 30 days for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma osteocalcin levels showed a significant (P < 0.01 and P < 0.05, respectively) increase, whereas spine bone density and total body bone density significantly (P < 0.001 and P < 0.05, respectively) decreased after 3 and 6 months of GnRH-A administration. Conversely, in the ipriflavone-treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medically induced hypogonadism.
authors.affiliation: Department of Obstetrics and Gynecology Piero Fioretti, S. Chiara Hospital, Pisa, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gambacciani
authors.forename: B
authors.initials: B
authors.lastname: Cappagli
authors.forename: L
authors.initials: L
authors.lastname: Piaggesi
authors.forename: M
authors.initials: M
authors.lastname: Ciaponi
authors.forename: A R
authors.initials: AR
authors.lastname: Genazzani
mesh_terms: D015502:Absorptiometry, Photon; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007006:Hypogonadism / Q000139:chemically induced / Q000150:complications; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007889:Leiomyoma / Q000188:drug therapy; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008159:Lumbar Vertebrae / Q000502:physiology; D008593:Menopause / Q000502:physiology; D008796:Metrorrhagia / Q000188:drug therapy; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy; D014599:Uterus / Q000187:drug effects / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007529:Isoflavones; D007987:Gonadotropin-Releasing Hormone; C018986:ipriflavone; D016729:Leuprolide